Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 308 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials June 29, 2018 Bjorn Saven: “By supporting early career researchers to do their jobs... November 19, 2021 Building on Success, Maximizing Opportunities: NCI’s Annual Plan & Budget Proposal September 4, 2019 AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 Load more HOT NEWS Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... NCI-MATCH Update: More Labs, New Arms, and Initial Findings Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow Women in science: Cancer research pioneers – part 2
